Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis

Journal of Clinical Pharmacology

Volumn 46, Issue 6, 2006, Pages 662-673

  Dang, Lily ^a   Duffull, Stephen ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Gentamicin; Hemodialysis; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN;

AREA UNDER THE CURVE; ARTICLE; DIFFUSION COEFFICIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MODEL; NEPHROTOXICITY; OTOTOXICITY; RETROSPECTIVE STUDY; SIMULATION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FEMALE; GENTAMICINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MODELS, BIOLOGICAL; RENAL DIALYSIS;

EID: 33745285694     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006286902     Document Type: Article

References (31)

1. Maisonneuve P, Agodoa L, Gellert R, Stewart JH. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93-99.
2. Stoves J, Bartlett CN, Newstead CG. Specialist follow-up of patients before end stage renal failure and its relationship to survival on dialysis. Postgrad Med J. 2001;77:586-593.
3. Amin NB, Padhi ID, Touchette MA, Patel RV, Dunfee TP, Anandan JV. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis. 1999;34:222-227.
4. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001;120:1883-1888.
5. Jean G, Charra B, Chazot C, Vanel T. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron. 2002;91:399-410.
6. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev. 1994;13:207-234.
7. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol. 1997;17:27-33.
8. Spicer J, Christiansen K, Currie B, et al. Therapeutic Guidelines: Antibiotic. 11th ed. Melbourne, Australia: Therapeutic Guidelines Limited; 2000.
9. Keller F, Borner K, Schwarz A, Offermann G, Lode H. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit. 1987;9:148-153.
10. Garraffo R. Optimal adaptive control of pharmacodynamic effects with aminoglycoside antibiotics: a required approach for the future. Int J Bio-Med Comp. 1994;36:43-57.
11. Matsuo H, Hayashi J, Ono K, et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother. 1997;41:2597-2601.
12. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet. 1994;27:32-48.
13. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: importance of effective dosage regimens. Drugs. 2001;61:713-721.
14. Barclay ML, Begg EJ, Duffull SB, Buttimore R. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust NZ J Med. 1995;25:230-235.
15. Mac-kay MV, Fernandez IP, Burson JS, Herrero GF. Experimental equations to calculate aminoglycoside clearances through Cuprophan dialyzers. Biopharm Drug Dispos. 1998;19:555-561.
16. Christopher TG, Korn D, Blair AD, Forrey AW, O'Neill MA, Cutler RE. Gentamicin pharmacokinetics during hemodialysis. Kidney Int. 1974;6:38-44.
17. Halpren BA, Axline SG, Coplon NS, Brown DM. Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. J Infect Dis. 1976;133:627-636.
18. Matzke GR, Halstenson CE, Keane WF. Hemodialysis elimination rates and clearance of gentamicin and tobramycin. Antimicrob Agents Chemother. 1984;25:128-130.
19. Danish M, Schultz R, Jusko WJ. Pharmacokinetics of gentamicin and kanamycin during hemodialysis. Antimicrob Agents Chemother. 1974;6:841-847.
20. Letourneau-Saheb L, Lapierre L, Daineault R, Prud'Homme M, St-Louis G, Sirois G. Gentamicin pharmacokinetics during hemodialysis in patients suffering from chronic renal failure. Int J Clin Pharmacol. 1977;15:116-120.
21. Lockwood WR, Bower JD. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother. 1973;3:125-129.
22. Giancoli DC. Physics: Principles With Applications. 5th ed. Upper Saddle River, New Jersey: Prentice-Hall; 1998.
23. Mould DR. Defining covariate distribution models for clinical trial simulation. In: Kimko HC, Duffull SB, eds. Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Perspective. Vol. 125. New York, NY: Marcel Dekker; 2002:31-54.
24. Holford NH. Input-output models. In: Kimko HC, Duffull SB, eds. Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Perspective. Vol. 125. New York, NY: Marcel Dekker; 2002:2-31.
25. Kastrissios H, Girard P. Protocol deviations and execution models. In: Kimko HC, Duffull SB, eds. Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Perspective. Vol. 125. New York, NY: Marcel Dekker; 2002:55-73.
26. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605-609.
27. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549-1555.
28. Kirkpatrick CMJ, Duffull SB, Begg EJ. Once daily aminoglycoside therapy: potential ototoxicity. Antimicrob Agents Chemother. 1997;41:879-880.
29. Moore RD, Man PSL. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
30. Kashuba ADM, Nafzuger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for noxocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623-629.
31. Zelenitsky SA, Harding GKM, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimocrob Chemother. 2003;52:668-674.